FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to cardiology, cardio-oncology, oncology and oncohaematology, and can be used to determine the probability of developing cardiovascular toxicity in cancer patients with underlying six-month anticancer therapy according to the R-CHOP regimen. Speckle-tracking echocardiographic examination is performed at rest, in a lying position, through the left parasternal/apical approaches and end-systolic volume, end-systolic size and global longitudinal systolic deformation of the left ventricle are determined. These values are used to calculate a coefficient P reflecting the risk of developing cardiotoxicity. If P>27.4322%, a high risk of developing cardiotoxicity is predicted, while P<27.4322% a low risk of developing cardiotoxicity is predicted.
EFFECT: method enables the well-timed revision of the main therapeutic approach to the patient, prescribing a cardioprotective therapy and avoiding fatal cardiovascular complications by calculating a coefficient P reflecting the risk of developing cardiotoxicity.
1 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING THE RISK OF DEVELOPING SUBCLINICAL LEFT VENTRICULAR SYSTOLIC DYSFUNCTION IN THE PATIENTS WITH CHRONIC LYMPHATIC LEUKEMIA IN THE CHEMOTHERAPY IN THE FCR MODE | 2019 |
|
RU2727003C1 |
| METHOD OF MANAGING PATIENTS WITH CHRONIC LYMPHATIC LEUKEMIA IN A POLYCHEMOTHERAPY ACCORDING TO A FCR SCHEME AIMED AT PREVENTING CARDIOTOXICITY | 2019 |
|
RU2722111C1 |
| METHOD FOR PREDICTION OF LETHAL OUTCOME IN PATIENTS WITH ISCHEMIC STROKE | 2023 |
|
RU2817260C1 |
| METHOD FOR MULTIVARIATE PREDICTION OF CHRONIC HEART FAILURE AFTER PRIMARY MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION DURING 48-WEEK FOLLOW-UP | 2021 |
|
RU2754798C1 |
| METHOD FOR PREDICTING THE DEVELOPMENT OF CARDIOTOXICITY IN PATIENTS WITH HER2 POSITIVE BREAST CANCER OF INITIALLY LOW / MODERATE CARDIOVASCULAR RISK RECEIVING A TARGETED THERAPY WITH TRASTUZUMAB AFTER ANTHRACYCLINE-CONTAINING CHEMOTHERAPY | 2020 |
|
RU2741371C1 |
| METHOD FOR ASSESSING LEFT VENTRICULAR MYOCARDIAL DEFORMATION IN SMOKERS WITH EARLY STAGES OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE OF LIGHT DEGREE AND ARTERIAL HYPERTENSION OF I STAGE | 2020 |
|
RU2743245C1 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPING LEFT VENTRICULAR GLOBAL LONGITUDINAL DEFORMITY AFTER COVID-19 PNEUMONIA IN INDIVIDUALS WITHOUT PULMONARY EMBOLISM, PERIPHERAL THROMBOSIS, CORONARY HEART DISEASE, AND ATRIAL FIBRILLATION | 2022 |
|
RU2782299C1 |
| METHOD FOR ASSESSING SUBCLINICAL CARDIOTOXICITY OF CHEMO- AND TARGETED THERAPY USING ECHOCARDIOGRAPHIC DIAGNOSTICS | 2022 |
|
RU2815813C1 |
| METHOD FOR PREDICTING UNFAVORABLE CARDIOVASCULAR OUTCOMES OF ACUTE CORONARY SYNDROME DURING HOSPITAL PERIOD IN PATIENTS WITH ONCOLOGICAL DISEASES | 2020 |
|
RU2751808C1 |
| METHOD FOR PREDICTING THE DEVELOPMENT OF THE LEFT VENTRICULAR SYSTOLIC DYSFUNCTION IN PATIENTS SUFFERING FROM ANKYLOSING SPONDYLITIS | 2022 |
|
RU2790770C1 |
